DURECT Toekomstige groei
Future criteriumcontroles 2/6
DURECT is forecast to grow earnings and revenue by 33.2% and 56% per annum respectively while EPS is expected to grow by 32.6% per annum.
Belangrijke informatie
33.2%
Groei van de winst
32.6%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 23.7% |
Inkomstengroei | 56.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 25 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts
Aug 08Durect names ex-RBC Capital Markets executive as CFO
Jul 05Is DURECT (NASDAQ:DRRX) A Risky Investment?
May 12DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be
Mar 14DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 10Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?
Jan 08Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?
Aug 05Durect (DRRX) Investor Presentation - Slideshow
May 06Durect EPS misses by $0.01, misses on revenue
May 04DURECT prices ~$43M stock offering
Feb 04DURECT surges after FDA approval for Posimir
Feb 02Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.
Dec 16DURECT (DRRX) Investor Presentation - Slideshow
Oct 31Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 23 | -38 | N/A | N/A | 1 |
12/31/2025 | 8 | -38 | N/A | N/A | 2 |
12/31/2024 | 8 | -26 | N/A | N/A | 3 |
6/30/2024 | 8 | -16 | -26 | -26 | N/A |
3/31/2024 | 8 | -23 | -32 | -32 | N/A |
12/31/2023 | 9 | -28 | -34 | -34 | N/A |
9/30/2023 | 9 | -37 | -35 | -34 | N/A |
6/30/2023 | 19 | -36 | -29 | -29 | N/A |
3/31/2023 | 19 | -36 | -30 | -30 | N/A |
12/31/2022 | 19 | -35 | -26 | -26 | N/A |
9/30/2022 | 23 | -32 | -29 | -29 | N/A |
6/30/2022 | 13 | -39 | -34 | -34 | N/A |
3/31/2022 | 14 | -37 | -32 | -32 | N/A |
12/31/2021 | 14 | -36 | -38 | -37 | N/A |
9/30/2021 | 9 | -38 | -35 | -35 | N/A |
6/30/2021 | 9 | -37 | -36 | -36 | N/A |
3/31/2021 | 31 | -14 | -37 | -37 | N/A |
12/31/2020 | 30 | -14 | -39 | -39 | N/A |
9/30/2020 | 34 | -11 | -27 | -26 | N/A |
6/30/2020 | 43 | -3 | 1 | 1 | N/A |
3/31/2020 | 23 | -24 | 4 | 4 | N/A |
12/31/2019 | 25 | -21 | 11 | 11 | N/A |
9/30/2019 | 23 | -24 | 1 | 1 | N/A |
6/30/2019 | 20 | -24 | -19 | -19 | N/A |
3/31/2019 | 19 | -24 | -19 | -19 | N/A |
12/31/2018 | 15 | -25 | -20 | -20 | N/A |
9/30/2018 | 34 | -10 | -21 | -21 | N/A |
6/30/2018 | 35 | -1 | -17 | -17 | N/A |
3/31/2018 | 36 | -4 | N/A | 1 | N/A |
12/31/2017 | 37 | -4 | N/A | -1 | N/A |
9/30/2017 | 21 | -21 | N/A | -1 | N/A |
6/30/2017 | 16 | -36 | N/A | -10 | N/A |
3/31/2017 | 15 | -35 | N/A | -30 | N/A |
12/31/2016 | 14 | -35 | N/A | -27 | N/A |
9/30/2016 | 16 | -32 | N/A | -26 | N/A |
6/30/2016 | 17 | -29 | N/A | -25 | N/A |
3/31/2016 | 18 | -26 | N/A | -22 | N/A |
12/31/2015 | 19 | -23 | N/A | -21 | N/A |
9/30/2015 | 18 | -23 | N/A | -17 | N/A |
6/30/2015 | 18 | -23 | N/A | -17 | N/A |
3/31/2015 | 18 | -23 | N/A | -17 | N/A |
12/31/2014 | 19 | -22 | N/A | -15 | N/A |
9/30/2014 | 19 | -21 | N/A | -15 | N/A |
6/30/2014 | 18 | -20 | N/A | -15 | N/A |
3/31/2014 | 17 | -20 | N/A | -15 | N/A |
12/31/2013 | 15 | -21 | N/A | -15 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: DRRX is forecast to remain unprofitable over the next 3 years.
Winst versus markt: DRRX is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: DRRX is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: DRRX's revenue (56% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: DRRX's revenue (56% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if DRRX's Return on Equity is forecast to be high in 3 years time